| Model Number |
3000 |
| Medical Device Problem Codes |
Calcified (1077); Insufficient Device Problem Information (3190)
|
| Health Effect - Clinical Codes |
Heart Failure/Congestive Heart Failure (4446); Insufficient Information (4580)
|
| Date of Event |
05/23/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
H10: additional manufacturer narrative: the subject device is not available for evaluation, as it remains implanted in the patient.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
| |
|
Event or Problem Description
|
|
It was reported that a patient with a 23mm 3000 aortic valve, underwent a valve-in-valve procedure after an implant duration of 8 years, 7 months due to unknown reason.The tavr was successfully performed with a 23mm 9755rsl valve.
|
| |
|
Additional Manufacturer Narrative
|
|
Svd is a logical and expected consequence of the chemical, mechanical, and immunological processes associated with bhv implantation.The common endpoint of all these factors is calcification and degradation.Svd is an acquired condition, intrinsic to bioprosthetic valves, characterized by deterioration of the leaflets or supporting structures, leading to thickening, calcification, tearing, or disruption of the prosthetic valve materials.These changes result in valvular dysfunction manifesting as stenosis and/or regurgitation with a consequent drop in hemodynamic efficacy of the valve.Despite the advancements in the heart valve industry, svd commonly begins 7- 8 years after implantation, with a considerably increased rate in patients with pertinent comorbidities and/or an implant duration of greater than 10 years.Prior investigations and extensive literature review have shown that svd is predominantly related to patient factors and implant duration rather than to manufacturing issues.Events related to device design, manufacturing, or use error tend to manifest at an earlier implant duration.The instructions for use (ifu) have been reviewed, and no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.The reported type of event is included in the ifu.There is no evidence to suggest a manufacturing defect caused or contributed to the reported event.Based on the information available, the most likely root cause is patient factors, including an implant duration of 7 or more years, chronic kidney disease (ckd) and coronary artery disease (cad).
|
| |
|
Additional Manufacturer Narrative
|
|
H10: additional manufacturer narrative: updated sections: b5, b7, g3, g6, h2, h6 (component code, clinical code, device code).
|
| |
|
Event or Problem Description
|
|
It was reported that a patient with a 23mm 3000 aortic valve, underwent a valve-in-valve procedure after an implant duration of 8 years, 7 months due to calcification leading to stenosis.The patient presented with heart failure and shortness of breath.The tavr was successfully performed with a 23mm 9755rsl valve.The patient was stable post-procedure and was discharged on pod #4.
|
| |
|
Search Alerts/Recalls
|